Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy

Moriguchi, Kota; Miyamoto, Katsuichi; Takada, Kazuo; Kusunoki, Susumu

doi:10.1016/j.jneuroim.2011.08.005

Cited by 40 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, the anti-GalNAc-GD1a antibody was reported as a candidate biological marker for predicting response to immune therapy (14). In the present study, a low titer of the IgG antibodies against gangliosides was shown in two cases, however, this finding might be a consequence of neural damage rather than its cause.…”

Section: Discussioncontrasting

confidence: 51%

“…Her neurological impairments fully recovered after IVIG and MPPT (20). Moriguchi et al reported three cases of anti-ganglioside antibody-positive NA who were treated with IVIg, and two of three patients showed good clinical response (14). In these reports, IVIg was begun in a relatively early disease phase, and was effective in non-responders to corticosteroid therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Serum titres of both IgM and IgG antibodies against 11 gangliosides (GM1, GM2, GM3, GD1a, GD1b, GD3, GT1b, GQ1b, CA1, Gal-C, and GalNAc-GD1a) were measured by enzyme-linked immunosorbent assay (ELISA) as described previously (13,14). Serum monoclonal proteins were examined by immunofixation electrophoresis assay.…”

Section: Laboratory Testsmentioning

confidence: 99%

See 2 more Smart Citations

Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases

et al. 2012

Self Cite

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 51%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases

et al. 2012

Self Cite

View full text Add to dashboard Cite

“…As it is likely that neuralgic amyotrophy attacks are ultimately induced by an auto-immune response to the peripheral nervous system [1][2][3][4][5], efforts have been undertaken to attempt treatment in the acute phase with immunomodulants such as corticosteroids or iv gammaglobuline [6][7][8][9][10][11]. Unfortunately, a randomized controlled trial of corticosteroids failed because it proved impossible to recruit the needed number of participants within the three-year trial period.…”

Section: Introductionmentioning

confidence: 99%

Incidence of neuralgic amyotrophy (Parsonage–Turner syndrome) in a primary care setting: A prospective cohort study

Alfen

Groothuis

Nobacht³

et al. 2015

Neuromuscular Disorders

View full text Add to dashboard Cite

ObjectiveNeuralgic amyotrophy is considered a rare peripheral nervous system disorder but in practice seems grossly under recognized, which negatively affects care for these patients. In this study we prospectively counted the one-year incidence rate of classic neuralgic amyotrophy in a primary care setting. MethodsIn a prospective cohort study during the year 2012 we registered all new cases of neck, shoulder or arm complaints from two large primary care centers serving a population of 14,118. Prior to study, general practitioners received a short training on how to diagnose classic neuralgic amyotrophy. Neuralgic amyotrophy was defined according to published criteria irrespective of family history. Only patients with a classic phenotype were counted as definite cases. After inclusion, patients with suspected neuralgic amyotrophy who had not yet seen a neurologist were offered neurologic evaluation for diagnostic confirmation. ResultsOf the 492 patients identified with new onset neck, shoulder or arm complaints, 34 were suspected of having neuralgic amyotrophy. After neurologic evaluation the diagnosis was confirmed in 14 patients. This amounts to a one-year incidence rate for classic neuralgic amyotrophy of 1 per 1000. Data Availability Statement: No centralized data collection was available for this study. Data were collected in an anonymized digital datafile and stored locally by the study group. The primary data file for this study is available as S1 Datafile.Funding: This study was sponsored by an unsolicited and unconditional gift from the Dutch Rare Diseases Fund (Stichting Zeldzame Ziekten Fonds; www.zzf.nl) and the ZABAWAS Foundation (www. zabawas.nl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ConclusionsOur findings suggest that neuralgic amyotrophy is 30-50 times more common than previously thought. Unawareness of the disorder and its clinical presentation seems the most likely explanation for this difference. An incidence rate of 1 per 1000 and the long-term sequelae many patients suffer warrant more vigilance in diagnosing the disorder, to pave the way for timely treatment and prevent complications.

show abstract

“…However, recent reports show that the functional prognosis is not as good as has been assumed [5]. Recently, glucocorticoid [17], IVIG [18], and the combination of glucocorticoid and IVIG [19] have been reported to hasten the recovery of NA if treatment begins in the early phase of the disease (within 1 month). In the present case, we tried a combination of glucocorticoid and IVIG followed by anti-herpes therapy 6 weeks after the onset of symptoms.…”

Section: Discussionmentioning

confidence: 99%

A Case of Neuralgic Amyotrophy in the Lower Extremity: A Possible Relationship with Herpes Zoster Virus Reactivation

Yoshioka¹

2016

CSMC

View full text Add to dashboard Cite

Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy

Cited by 40 publications

References 12 publications

Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases

Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases

Incidence of neuralgic amyotrophy (Parsonage–Turner syndrome) in a primary care setting: A prospective cohort study

A Case of Neuralgic Amyotrophy in the Lower Extremity: A Possible Relationship with Herpes Zoster Virus Reactivation

Contact Info

Product

Resources

About